GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Subfertility
About this trial
This is an interventional treatment trial for Subfertility focused on measuring subfertility, IVF, FET, dual trigger, luteal phase support, Gonadotrophin releasing hormone agonist, live birth rate
Eligibility Criteria
IVF
Inclusion criteria:
- Women aged <43 years at the time of IVF treatment
Exclusion criteria:
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
- Women at risk of OHSS
FET
Inclusion criteria:
- Women aged <43 years at the time of IVF treatment
- Replacing early cleavage embryos or blastocysts after thawing
- FET in natural cycles
Exclusion criteria:
- Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient
- Preimplantation genetic diagnosis treatment
- Use of donor oocytes or donor embryos
- Hydrosalpinx shown on pelvic scanning and not surgically treated
Sites / Locations
- Department of Obstetrics and GynaecologyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Placebo Comparator
Active Comparator
Placebo Comparator
IVF: dual trigger
IVF: hCG trigger
FET: agonist
FET: control
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
On the day of FET, normal saline will be injected subcutaneously.